We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Oryzon (ORY.MC) is a public company listed in the Madrid and part of the IBEX-Small Cap Index. It is now one of the most liquid companies in this segment of the market. Oryzon is clinical stage Biopharmaceutical Company that, with its Epigenetic Platform, develops first-in-class drugs for diseases with strong unmet medical need such as cancer and neurodegenerative diseases. Oryzon’s pipeline includes inhibitors against Histone demethylases, with a strong specialization in KDM1A (LSD1).
Oryzon is leading epigenetics in CNS with Vafidemstat, a brain penetrant dual LSD1-MAOB inhibitor being explored on three different Phase IIA trials: in mil-moderate AD; in a basket trial in aggressivity covering three different psychiatric indications like like ASD, ADHD and BLP and a third one in RR/SP-MS. Oryzon has also an oncology program, iadademstat, this is a highly selective LSD1 inhibitor being explored in two Phase IIA trials, one in AML and the other in SCLC in a biomarker guided trial.